The disclosure provides plasminogen activator inhibitor-1 (PAI-1 ) antibodies or antibody fragments, which immunospecifically bind to a selective eptope of human plasminogen activator inhibitor-1 (PAI-1 ). The disclosure further provides sequence variants of CDR1, CDR2, and CDR3 of the heavy chain and light chain variable regions of the antibodies. Diseases or conditions that can be treated with the antibodies are also disclosed.Linvention porte sur des anticorps ou sur des fragments danticorps anti-PAI-1 et sur leurs procédés dutilisation.